NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity ...

Top-Line Data Expected in the Fourth Quarter of 2025 CAMBRIDGE, Mass., July 9, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology ...

Skye’s Nimacimab shows promise in obesity treatment with lean mass preservation. Phase 2a results slated for 2025 could drive ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Wave Life Sciences could offer significant upside if obesity candidate WVE-007 delivers strong human data. Check out the ...

Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all ...

Trend alert! Split dosing, stretch dosing, skip dosing, microdosing Ozempic… People are finding creative ways to use ...

Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ... When Dushay is looking through a patient’s medical chart, she says, her stomach churns when she sees the little box that ...

Another major insurance change coming next year will affect another large swath of Dushay’s patients: In January, BCBS ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

The TGA urged doctors to warn Ozempic users to 'be careful' and check the dose before administering it. Earlier this month, ...

Patients have been referred to hospital emergency departments after mistakenly overdosing on diabetes drugs such as Ozempic, ...